Effect of statin therapy on cardiovascular outcomes after coronary revascularization in patients ≥80 years of age: Observations from the CREDO-Kyoto Registry Cohort-2

Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly

“…Cumulative incidences of MACE, all-cause and CV death, stroke and coronary revascularization were also significantly lower in statin users vs non users, whereas MI rate did not differ between the statin and no-statin groups [1]. Interestingly, adjusted hazard ratios (HR) for all CV outcomes, except for MI, were lower in the superelder group compared with the non-super-elder group (0.77 vs 0.82 for MACE, 0.76 vs 0.77 for all-cause death, 0.74 vs 0.76 for CV death, 0.75 vs 0.81 for stroke and 0.88 vs 0.92 for coronary revascularization, respectively).Gender and baseline LDL-C levels did not affect the results for both patient groups [1]. However, in the super-elder group, patients treated with potent statins and those achieving LDL-C levels <100 mg/dl tended to have lower MACE rates compared with those on a standard statin and those with on-treatment LDL-C levels 100 mg/dl, respectively.…”

“…Gender and baseline LDL-C levels did not affect the results for both patient groups [1]. However, in the super-elder group, patients treated with potent statins and those achieving LDL-C levels <100 mg/dl tended to have lower MACE rates compared with those on a standard statin and those with on-treatment LDL-C levels 100 mg/dl, respectively.…”

“…smoking, dialysis, CABG and chronic total occlusion were more frequent in the non-super-elder group [1]. Baseline lipid levels, statin use and proportion of prescribed potent statins were significantly lower in the super-elder patients compared with nonsuper-elder group.…”

“…With regard to very low LDL-C levels, cumulative incidences of MACE were similar between patients with LDL-C <80 mg/dl and 80e99 mg/dl. In the non-super-elder group, cumulative rates of MACE was significantly lower in potent statin users vs those on a standard statin, whereas no difference was observed with regard to achieved LDL-C levels [1].With the increase in the proportion of elderly in most countries as well as the fact that CV risk rises with age, it is important to DOI of original article: http://dx. …”

“…

In this issue of Atherosclerosis, Natsuaki et al [1] reported the effects of statin treatment on major adverse cardiovascular (CV) events [MACE: composite of CV death, myocardial infarction (MI) and stroke] in patients 80 years undergoing first coronary revascularization i.e. percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in the CREDO-Kyoto (Coronary REvascularization Demonstrating Outcome study in Kyoto) PCI/CABG registry cohort-2.

…”